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Congenital Joint Dislocations Caused by Carbohydrate
Sulfotransferase 3 Deficiency in Recessive
Larsen Syndrome and Humero-Spinal Dysostosis
Pia Hermanns,1,9 Sheila Unger,1,2,9 Antonio Rossi,3 Antonio Perez-Aytes,4 Hector Cortina,4
Luisa Bonafe´,5 Loredana Boccone,6 Valeria Setzu,6 Michel Dutoit,5 Luca Sangiorgi,7 Fabio Pecora,3
Kerstin Reicherter,1 Gen Nishimura,8 Ju¨rgen Spranger,1 Bernhard Zabel,1,2 and Andrea Superti-Furga1,*
Deﬁciency of carbohydrate sulfotransferase 3 (CHST3; also known as chondroitin-6-sulfotransferase) has been reported in a single kin-
dred so far and in association with a phenotype of severe chondrodysplasia with progressive spinal involvement. We report eight CHST3
mutations in six unrelated individuals who presented at birth with congenital joint dislocations. These patients had been given a diag-
nosis of either Larsen syndrome (three individuals) or humero-spinal dysostosis (three individuals), and their clinical features included
congenital dislocation of the knees, elbow joint dysplasia with subluxation and limited extension, hip dysplasia or dislocation, clubfoot,
short stature, and kyphoscoliosis developing in late childhood. Analysis of chondroitin sulfate proteoglycans in dermal ﬁbroblasts
showedmarkedly decreased 6-O-sulfation but enhanced 4-O-sulfation, conﬁrming functional impairment of CHST3 and distinguishing
them from diastrophic dysplasia sulphate transporter (DTDST)-deﬁcient cells. These observations provide a molecular basis for recessive
Larsen syndrome and indicate that recessive Larsen syndrome, humero-spinal dysostosis, and spondyloepiphyseal dysplasia Omani type
form a phenotypic spectrum.Proteoglycans rank among the most important compo-
nents of connective tissues. They consist of glycosamino-
glycan (GAG) polymer chains attached to core proteins.
The sugar composition of the glycosaminoglycan (e.g.,
chondroitin, dermatan, heparan) and the nature of the
core protein give rise to a great variety of proteoglycans,
macromolecules with different biological roles and tissue
distributions, such as aggrecan in cartilage and decorin
and biglycan in skin.1 Most GAGs are heavily sulfated,
and it is believed that sulfation is crucial to the biological
role of GAGs because it forms an array of regularly spaced
negative charges.
A mutation in the gene coding for carbohydrate sulfo-
transferase 3 (CHST3, chondroitin 6-sulfotransferase;
MIM 603799) has been reported in a family originating
from Oman and was associated with a phenotype de-
scribed as spondyloepiphyseal dysplasia with spinal mis-
alignment and joint abnormalities (spondyloepiphyseal
dysplasia, Omani type; SED-OT; MIM 608637).2,3 Studies
in cells cultured from affected individuals conﬁrmed the
impairment of 6-sulfation on N-acetyl-D-galactosamine
residues in chondroitin GAG chains. The clinical descrip-
tion emphasized the chondrodysplasia aspect rather than
the neonatal presentation, and no subsequent patients
have been identiﬁed.
Larsen syndrome is the name given to a condition char-
acterized by multiple congenital dislocations, and a subset
of Larsen syndrome cases (LRS1 [MIM 150250])4–6 is1368 The American Journal of Human Genetics 82, 1368–1374, Junecaused by disturbance to the cytoskeleton from dominant
mutations in the gene coding for ﬁlamin B (FLNB; MIM
150250). However, Larsen syndrome is genetically and
molecularly heterogeneous, with a number of cases being
inherited as recessive traits, such as the variant that is par-
ticularly frequent on Reunion Island (so-called ‘‘Ile de la
Re´union’’ variant of Larsen syndrome) (MIM 245600).7,8
These cases have more severe joint disease but lack the
characteristic ﬂat face of dominant Larsen syndrome that
was emphasized in the original publication.4,5
Humero-spinal dysostosis (HSD [MIM 143095]) was the
name given by Kozlowski et al. to two (putative) half-sibs
with a combination of dislocating knees, bilateral clubfoot,
elbow joint dysplasia, and coronal clefting and superior and
inferior notching of the lumbar vertebral bodies.9 The con-
dition has been diagnosed rarely, with only a handful of
cases reported, although the phenotype in the reported
cases is very homogeneous.9–12 It is likely that similar cases
have been simply diagnosed as Larsen syndrome. The in-
heritanceofHSD remainedunclear because itwasuncertain
whether the two original cases were full or half sibs,9 and all
other cases have been sporadic.
We report here on the identiﬁcation ofCHST3mutations
in six individuals born with joint dislocations: Three had
been diagnosed with Larsen syndrome, three with HSD.
All six of our patients are the only affected people in
their families, and only one family is known to be consan-
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Table 1. Overview of Genetic Data and Results on the Families Reported in This Study
Patient
No. Ethnicity
Parental
Consan-
guinity
Unaffected
Sibs
Maternal
CHST3
Allele
Paternal
CHST3
Allele
Short
Stature
at
Birth
Breech
Presenta-
tion
Postnatal
Short
Stature
(percentile)
Elbow Joint
Subluxation
or Limited
Extension
Hip
Dysplasia
or
Disloca-
tion
Knee
Luxation
or Genu
Recur-
vatum
Club
feet
1 Turkish-
German
yes 1 brother c.776T/C,
L259P
c.776T/C,
L259P
þ þ yes; 100.2 cm
at 10 yr (<3rd)
þ þ þ þ
2 Swiss
(Valais)
no, but
same
small
village
1 brother c.664C/T,
R222W
c.664C/T,
R222W
not
recorded
no yes; 125 cm
at 16 yr (<3rd)
þ þ þ þ
3 Sardinian no none
(only child)
c.920T/C,
L307P
c.920T/C,
L307P
þ þ yes; 99 cm at
6 yr (<3rd)
þ þ þ þ
4 Spanish
(Central Spain)
no 1 sister c.1086 delG,
G363A fsX393
c.603C/A,
Y201X
not
recorded
no yes: 134 cm
adult height
(<3rd)
þ þ þ þ
5 Spanish no 1 sister c.617-618 TC/
CA,
F206X
IVS2 1G/
C and
c.141G/C
(adjacent
nucleotides),
missplicing?
þ þ yes, 90 cm at
5 yr (<3rd)
þ no þ þ
6 Spanish no 1 sister c.1086 delG,
G363AfsX393
c.1114G/A,
E372K
þ no yes; 77cm at 2.5
yr (<3rd)
þ no þ þgeographically isolated regions and have homozygous
mutations, indicating possible distant consanguinity
(Table 1). At least three patients were delivered by Cesarean
section on account of breech presentation. Birth lengthwas
below the third percentile in all patients where recorded,
but only one child was noted to have short limbs on ultra-
sound (patient 5). Birth lengths ranged from 41.5 cm to
44 cm. All patients had a height signiﬁcantly below the
third percentile at last examination. Our lone adult patient
(patient 4), whose clinical and radiographic features at age
2 yr have been published as an example of HSD,10 achieved
a ﬁnal height of 134 cm. Congenital joint dislocations were
present in all children and were the presenting feature for
ﬁve out of six patients (Figure 1, Table 1). Six of six patients
had congenital clubfeet and knee dislocations, with three
having genu recurvatum. Four of six had hip luxation,
and six of six had radial head dislocation. All children
have had multiple orthopedic procedures on the knees
and feet, with variable success. All patients have residual
joint restriction, and the older patients, presently aged
31 yr (patient 4), 17 yr (patient 2), and 10.5 yr (patient 1),
all needed aids (crutches, wheelchair) for ambulation. Spi-
nal radiographs of the three older patients (patients 1, 2,
and 4) show severe degeneration of the intervertebral disks
with thoracic kyphosis (not shown). Intellect, hearing, and
vision were normal in all. No children had cleft palate, and
nonehad the typical facial features of dominant Larsen syn-
drome: The facial features in childhood were normal but
reminiscent of diastrophic dysplasia with small mouth,
small alae nasi, and high nasal bridge. The parents are all
of normal height and had no joint abnormalities. All hu-
man-subject studies have been carried out in accordance
with IRB requirements of the participating institutions.The AmTable 1 and Figure 2 show the CHST3 mutations identi-
ﬁed in the six patients. Formally, nine mutations on eight
different alleles (ﬁve missense mutations, three premature-
termination mutations, and one splice-site mutation) were
identiﬁed. All parents were shown to be heterozygous for
one of the mutations found in their child. Patients 1, 2,
and 3 were homozygous for point mutations leading to
amino acid substitutions. The genetic data are in accor-
dance with the pedigree, with family 1 being consanguin-
eous, family 2 originating from the same small village, and
family 3 originating from the island of Sardinia, where
there is a relatively high degree of consanguinity. One mu-
tation (c.1086 delG) was seen in two different families. In
patient 5, an unusual mutation was found that involved
two adjacent nucleotides (GG/CC), the last nucleotide
of IVS2 (i.e., the second nucleotide of the canonical splice
acceptor site), and the ﬁrst nucleotide of exon 3 (the sec-
ond base of codon 47). Formally, the two single-nucleotide
substitutions can be described as IVS21G/C and
c.141G/C (R74S); subcloning the PCR product always
showed cosegregation of the two changes, and analysis
of the parents showed that the patient had inherited
both mutations from his father. Thus, the adjacent nucle-
otide substitutions were in cis and probably originated
from a single mutational event. Unfortunately, nomaterial
was available to determine whether the mutations resulted
in missplicing or in amino acid substitution R47S (or in
a combination of the two); mutation of two nucleotides
within a splicing-consensus sequence is highly likely to
affect splicing, and thus we will not consider R47S as a po-
tential amino acid substitution in the further discussion.
Several different lines of evidence suggest that the amino
acid substitutions observed (R222W, L259P, L307P, anderican Journal of Human Genetics 82, 1368–1374, June 2008 1369
Figure 1. Synopsis of Clinical Aspect and Main Radiographic Features
The first row shows congenital dislocation of the left knee and clubfoot in patient 3, diagnosed with Larsen syndrome, at a few days of age
(the appearance is identical to that of the HSD patient reported by Hall11). At birth, the left leg was extended in such a way that the foot
rested against the thoracic wall. The central photograph shows marked valgus deformity of the knees and bilateral clubfoot in patient 5 at
age 2 yr. The right panels show patient 1, a girl, at age 5 yr, after several surgical procedures had been carried out to stabilize the dis-
located knees and the dysplastic hips. Note also the inability to extend the elbows completely. The second row shows the bifid humerus
and radial dislocation, as well as the knee dislocation or subluxation with delayed development of the knee epiphyses (patient identi-
fication and ages are within the panels). The third row shows the diagnostically useful spinal changes: In the AP projection, there is
marked widening of the interpedicular space from T12 to L1 (the arrows mark the vertebral body of L1); the interpedicular space then
decreases progressively from L3 to L5. In the lateral projection, notching or scalloping of the upper and lower endplates of the lumbar
vertebral bodies can be seen; these changes have been emphasized in the original descriptions of humero-spinal dysostosis9,10. The
changes are more pronounced in the younger patients.1370 The American Journal of Human Genetics 82, 1368–1374, June 2008
Figure 2. Scheme of the CHST3 Gene and Protein
The upper part is a schematic representation of the CHST3 exon-intron structure and of the coding regions. Immediately below, the small
horizontal arrows indicate the position of primer couples used to amplify genomic DNA. The lower part is a schematic representation of
the CHST3 protein with its transmembrane domain and the intraluminal sulfotransferase domain as inferred from data on the Expasy site.
Above the protein are mutations leading to premature stop codons as well as the putative splicing mutation (see Table 1 and Supplemen-
tal Material and Methods, available online); below the proteins are amino acid substitutions, including the R304Q substitution reported
by Thiele et al.,2 and the known polymorphism R357Q.E372K) are pathogenic. First, all mutations segregated as
expected for a pathogenic mutation, with parents being
heterozygous for (only) one mutation in each family. Sec-
ond, all ﬁve substitutions affect amino acids that are highly
conserved (data not shown). Third, the substitutions are
nonconservative; R222W abolishes a charged residue,
E372K substitutes a negatively charged with a positively
charged residue, and L259P and L307P substitute the
aliphatic leucine with a helix-breaking proline. Fourth,
none of the respective sequence changes were seen in
any of a panel of over 70 unaffected controls (140 unre-
lated chromosomes). Finally, in the two patients who con-
sented to donate skin biopsies (patient 1, L259P; patient 2,
R222W; both at homozygosity), evidence of severely im-
paired CHST3 activity was obtained in ﬁbroblast cultures
(see below). In these two cell lines, cDNA fragments har-
boring the mutations were ampliﬁed by quantitative RT-
PCR using primers spanning from exon 2 to exon 3 with
the same efﬁciency as in control lines (data not shown).
Mutations Y201X and F206X predict truncation of the pro-
tein including a large portion of the sulfotransferase
domain (Figure 1), whereas the frameshift deletion c.1086
delG would remove approximately one-fourth of the sulfo-
transferase domain and probably destabilize either the
mRNA (by nonsense-mediated decay) or the protein (by
adding a stretch of 30 missense amino acids). The individ-
uals in our small series appeared to have a phenotype of
similar severity and do not support the concept of a pheno-
typic gradient correlated with speciﬁc mutations.The AmThe consequence of the L259P and R222W mutations
on CHST3 function was tested in cultured skin ﬁbroblasts
from patient 1 and 2 by determining the sulfation pattern
of chondroitin sulfate chains. Cells were labeled with
[3H]glucosamine, a precursor for N-acetyl-D-galactos-
amine, and the sulfation of chondroitin sulfate PGs was
measured by HPLC disaccharide analysis after digestion
with chondroitinase ABC and ACII. The main disaccharide
constituents of chondroitin sulfate—DDi-0S, DDi-4S, and
DDi-6S—were measured. Labeling in standard medium
showed a 4- to 5-fold reduction of the relative amount of
DDi-6S in the patients’ ﬁbroblasts compared to the con-
trols (Figure 3). We previously observed that in cells from
patients with mutations in the sulfate transporter, DTDST
(SLC26A2), there was a relationship between the rate of PG
synthesis and the degree of total GAG sulfation.13 Thus,
we stimulated GAG synthesis in ﬁbroblast cultures by incu-
bation with b-D-xyloside, a compound that acts as a GAG-
chain initiator.14 In presence of 1 mM b-D-xyloside, the
overall incorporation of labeled glucosamine was higher
(data not shown) and the relative amount of DDi-0S de-
creased in all the cell lines, indicating that overall GAG
synthesis and sulfation was stimulated, as we had previ-
ously observed;13 in the patients’ cells, the relative amount
of DDi-6S was dramatically reduced, demonstrating that
both the L259P and R222W mutations severely impair or
abolish CHST3 function (Figure 3).
The clinical and radiographic features of our patients
with recessive Larsen syndrome and HSD are differenterican Journal of Human Genetics 82, 1368–1374, June 2008 1371
Figure 3. Disaccharide Composition of
Chondroitin Sulfate Synthesized by Fi-
broblast Cultures
Fibroblasts from two controls and from pa-
tients 1 and 2 were labeled simultaneously
with the radiolabeled glycosaminoglycan
sugar precursor, [6-3H]glucosamine, and
the chondroitin sulfate synthesized was
harvested, purified, and cleaved into its
constituent disaccharides, DDi-0S, DDi-4S
and DDi-6S. These were separated by
high-performance liquid chromatography
(HPLC) and measured (see Supplemental
Material and Methods). In patients’ cells,
the proportion of DDi-6S (black bars) is
markedly reduced at basal condition; under
stimulation of GAG synthesis with beta-D-
xylopiranoside, the difference between
controls and patients increases further. The bars show the percentage of each of the three disaccharides (and the standard error of
the mean) in each experiment. The statistical significance of the difference between the value of each disaccharide in the patient
cell lines and the mean of the same disaccharide in the two control lines was calculated with Student’s t test; * p < 0.01; ** p < 0.001.but complementary to those reported by Rajab et al. in the
older individuals in the Omani kindred.3 At birth, the
prominent clinical and skeletal features are short stature
of prenatal onset, dislocation or subluxation of the knee
joints, clubfeet, dysplasia of the distal humerus, and elbow
joint dysplasia with radial subluxation and limitation of
extension. Most cases have hip dislocation. The face is un-
like the dish-like face observed in classic Larsen syndrome
but is characteristic with small mouth, small and over-
folded ears, and small alae nasi. It resembles the face
seen in diastrophic dysplasia. Most affected individuals
had several surgical procedures to stabilize the hip and
knee joints. Later in childhood, progressive degenerative
arthritis of the hips leads to painful contractures; early
and severe degeneration of intervertebral disks leads to
short trunk, kyphoscoliosis, and eventually vertebral fu-
sion; and brachydactyly appears because of progressive rel-
ative shortening of the metacarpals. Although some of
the original patients with HSD had dysplasia of heart
valves,9,11 only one of our patient (patient 2) had cardiac
ﬁndings, namely, mild subvalvular aortic stenosis. Intelli-
gence has been normal in all cases; myopia and cleft palate
have not been observed. The diagnostically useful radio-
graphic ﬁndings are shown in Figure 1. Changes recogniz-
able at birth are misalignment or frank dislocation of the
knee joints; biﬁd distal humerus with subluxation of the
radial head; posterior and inferior scalloping or coronal
clefting of the lumbar vertebral bodies; and pronounced
widening of the interpedicular distance of L1 and L2
with reduction of the distance from L3 toward L5. The
hip joints have been dysplastic or dislocated in ﬁve of
our six cases. In childhood, signs of a moderate dysplasia
develop with secondary changes in the hip and knee joint,
shortening of the metacarpals (without frank brachydac-
tyly), and progressive degeneration of the intervertebral
disks leading to lumbar lordosis and thoracic kyphosis or1372 The American Journal of Human Genetics 82, 1368–1374, Junekyphoscoliosis with reduction of the intervertebral spaces
and, eventually, fusion of vertebral bodies.
The differential diagnosis of multiple dislocations in
a newborn is large, with Larsen syndrome being one of
the most common entities. The original description of
Larsen syndrome emphasized the congenital joint disloca-
tions and a characteristic ﬂat face.4,5 In clinical practice,
‘‘Larsen syndrome’’ is a diagnostic label that is applied to
conditions that are probably heterogeneous. Similarly, in-
dividuals diagnosed with HSD in the literature and in our
series were given that diagnosis as infants or young chil-
dren. All patients with recessive Larsen syndrome and
HSD had congenital joint dislocations but lacked the ﬂat
face typical of classic, dominant Larsen, and they had pro-
nounced vertebral changes that are instead not typical of
dominant Larsen syndrome.4,5,15 Larsen syndrome is fre-
quently caused by dominant mutations in the ﬁlamin B
(FLNB) gene,6,15 but it has long been known that a recessive
variant of Larsen syndrome exists with clinical features
that are similar to, but distinct from, those of dominant
Larsen syndrome.7,8 CHST3 deﬁciency is the ﬁrst molecu-
lar basis for the recessive variant of Larsen syndrome. Al-
though the incidence of CHST3-associated Larsen syn-
drome remains to be determined, there are reports of
Larsen syndrome that would ﬁt with CHST3 deﬁciency:
Weisenbach and Melegh reported two sibs with ‘‘Larsen
syndrome with vertebral changes’’; the clinical and radio-
graphic changes are identical of those reported in the pres-
ent paper.16 Joseph and Varghese reported a patient with
humeral dysplasia and dislocations and discussed the pos-
sibility that the condition may represent a variant of
Larsen syndrome.17
Several features may help in distinguishing CHST3-deﬁ-
cient recessive Larsen syndrome and HSD from classic
Larsen syndrome caused by dominant FLNB mutations.
Pre- and postnatal short stature are not typical of2008
dominant Larsen syndrome. Although congenital disloca-
tions are present in both conditions, in CHST3 deﬁciency
there is no generalized joint laxity; the dislocations are pro-
duced by primary joint dysplasia rather than joint laxity.
The development of severe spinal changes distinguishes
this condition from classic Larsen syndrome. Radiographi-
cally, themost distinctive features are a wide interpedicular
distance at L1, shortening and clefting of the lumbar verte-
brae in infancy, the presence of a biﬁd distal humerus with
dislocation or subluxation of the radial heads, and the de-
velopment of short metacarpals and phalanges. Supernu-
merary carpal bones are not seen, and bone age is not sig-
niﬁcantly advanced. The single feature most useful to
recognize CHST3 deﬁciency seems to be the dysostotic
changes in the thoracolumbar spine—namely, widening
of the interpedicular distance at L1 seen in the antero-pos-
terior projection and the short and cleft vertebral bodies in
the lateral projection—that were present in our patients.
These skeletal changes were mentioned by both Kozlowski
et al.9 and Cortina et al.10 in their descriptions of HSD, and
they are also recognizable in Figure 1 of the report on SED-
OT by Rajab et al.3 The affected individuals in the SED-OT
kindred reported by Rajab et al. were studied as older chil-
dren and adults; congenital dislocations were not men-
tioned, the vertebral clefting was no longer present, ky-
phoscoliosis and bone dysplastic changes were perceived
as more prominent, and the condition was described as
a form of spondyloepiphyseal dysplasia.3 It is possible
that had these patients been identiﬁed as newborns, they
might have had features compatible with HSD or recessive
Larsen syndrome. Only identiﬁcation of a larger cohort of
patients will allow us to determine the extent of overlap or
of identity of these three conditions.
The sulfate group transferred toN-acetylgalactosamineby
CHST3 is the same that is removed in the lysosomes byGal-
NAc-6-sulfatase (GALNS), the enzyme deﬁcient inmucopo-
lysaccharidosis type IV A (MPS IV A; Morquio syndrome
[MIM 253000]). Thus, there is a clinical phenotype associ-
ated with either sense of the reaction, highlighting the bio-
logical importanceof chondroitin6-sulfation inman. Inter-
estingly, the mouse differs from the human in this respect:
neither chondroitin-6-sulfotransferase (Chst3)-deﬁcient or
GalNAc-6-sulfatase (Galns)-deﬁcientmicedevelopa skeletal
phenotype.18,19 In contrast, micewith defects in the sulfate
transporter Slc26a2 (Dtd mouse)20 or in chondroitin-4-sul-
fotransferase 121 have strong skeletal phenotypes. Chon-
droitin 6-sulfate seems to be important for joint develop-
ment and homeostasis in humans but not in the mouse.
Fibroblasts from patients with mutations in either
the DTDST sulfate transporter (SLC26A2; MIM 606718)
or the CHST3 sulfotransferase show defective sulfation
of chondroitin proteoglycans that becomes more evident
when GAG-chain synthesis is stimulated with b-D-xylo-
side.13 Unlike in DTDST mutant cells, where both 4- and
6-sulfation are affected, the sulfation defect in CHST3-
deﬁcient cells is limited to the 6-position on galactosamine
in chondroitin, whereas the 4-position is highly sulfatedThe Am(Figure 3). The phenotypic difference between DTDST con-
ditions and CHST3 deﬁciency must be ascribed either to
different function of the 4-sulfation versus 6-sulfation
on chondroitin sulfate or to the degree of sulfation of other
glycosaminoglycans, affected in DTDST but not in CHST3
deﬁciency. Even in the presence of two putative CHST3
null mutations (Table 1, patient 4), the degree of chondro-
dysplasia is much milder than what is seen in the severe
DTDST disorders (achondrogenesis type 1B and atelosteo-
genesis type 2; MIM 600972 and 256050).22 By contrast,
dislocation and degeneration of articulations (at the hips,
knees, and spine) seem to be more prominent in CHST3
deﬁciency. Thus, when compared to DTDST deﬁciency,
CHST3 deﬁciency has a similar or more pronounced effect
on joint formation and articular homeostasis but a less se-
vere effect on endochondral growth of skeletal elements.
This seems to support the hitherto unproven hypothesis
that the sulfation defect in DTDST dysplasias can involve
proteoglycans other than chondroitin sulfate, such as hep-
aran sulfates, and inﬂuence FGFR signaling pathways in
the growth plate.23
In conclusion, CHST3 deﬁciency is a molecular basis for
two conditions with congenital joint dislocations such
as Larsen syndrome and HSD. Although the diagnostic
features for recessive Larsen syndrome, HSD, and SED-OT
are different, our results indicate that they constitute a rel-
atively narrow phenotypic spectrum and in fact may be
different age-related descriptions of the same condition.
The proportion of Larsen syndrome cases caused by
CHST3 deﬁciency remains to be determined. The possibil-
ity of molecular diagnosis will be useful in the manage-
ment and in the counseling of affected patients and their
families. Recessive Larsen syndrome is a second sulfation
disorder that is analogous to a dominant FLNB disorder,
the ﬁrst one being atelosteogenesis 2 (DTDST),22 which re-
sembles atelosteogenesis type 1/3 (FLNB; MIM 108720 and
108721);6 a molecular link between ﬁlamin B and proteo-
glycan sulfation seems likely and should be investigated.
Supplemental Data
A description of the methods used for molecular and biochemical
analysis and an alignment of CHST3 amino acids showing conser-
vation between species are available at http://www.ajhg.org/.
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